Related Experiment Video
Updated: Jun 21, 2026
Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model
Published on: September 27, 2024
Nanoparticle-delivered suicide gene therapy effectively reduces ovarian tumor burden in mice
Yu-Hung Huang1, Gregory T Zugates, Weidan Peng
1Lankenau Institute for Medical Research, Wynnewood, Pennsylvania 19096, USA.
Abstract:
There is currently no effective therapy for patients with advanced ovarian cancer. To address the need for a more effective treatment for this deadly disease, we conducted preclinical tests in ovarian tumor-bearing mice to evaluate the therapeutic efficacy of using a cationic biodegradable poly(beta-amino ester) polymer as a vector for nanoparticulate delivery of DNA encoding a diphtheria toxin suicide protein (DT-A). The promoter sequences of two genes that are highly active in ovarian tumor cells, MSLN and HE4, were used to target DT-A expression to tumor cells. Administration of DT-A nanoparticles directly to s.c. xenograft tumors and to the peritoneal cavity of mice bearing primary and metastatic ovarian tumors resulted in a significant reduction in tumor mass and a prolonged life span compared to control mice. Minimal nonspecific tissue and blood chemistry toxicity was observed following extended treatment with nanoparticles. DT-A nanoparticle therapy suppressed tumor growth more effectively than treatment with clinically relevant doses of cisplatin and paclitaxel. Our findings suggest that i.p. administration of polymeric nanoparticles to deliver DT-A encoding DNA, combined with transcriptional regulation to target gene expression to ovarian tumor cells, holds promise as an effective therapy for advanced-stage ovarian cancer.
Insights
New nanoparticle therapy shows promise for advanced ovarian cancer. Biodegradable polymers delivered DNA encoding a diphtheria toxin suicide gene, effectively reducing tumors and extending survival in preclinical models.
Area of Science:
- Biotechnology
- Oncology
- Nanomedicine
Background:
- Advanced ovarian cancer lacks effective therapeutic options.
- Novel treatment strategies are urgently needed to improve patient outcomes.
Purpose of the Study:
- To evaluate the therapeutic potential of a novel nanoparticle-based gene therapy for advanced ovarian cancer.
- To assess the efficacy and safety of delivering DNA encoding a diphtheria toxin suicide gene (DT-A) using a poly(beta-amino ester) polymer vector.
Main Methods:
- Preclinical studies were conducted in ovarian tumor-bearing mice.
- Cationic biodegradable poly(beta-amino ester) nanoparticles were used to deliver DT-A encoding DNA.
- Gene expression was targeted to ovarian tumor cells using MSLN and HE4 promoter sequences.
- Nanoparticles were administered directly to tumors and intraperitoneally.
Main Results:
- Significant reduction in tumor mass and prolonged lifespan observed in treated mice compared to controls.
- DT-A nanoparticle therapy demonstrated superior efficacy over cisplatin and paclitaxel.
- Minimal toxicity was observed with extended nanoparticle treatment.
Conclusions:
- Polymeric nanoparticle-mediated delivery of DT-A encoding DNA, with tumor-specific transcriptional regulation, is a promising therapeutic approach for advanced ovarian cancer.
- Intraperitoneal administration of these nanoparticles offers a potential treatment strategy.
Related Concept Videos
02:43Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
01:16In-vitro Mutagenesis